1461098091-ecb2cb22-38be-4a24-a72e-2b16956f6ba5

1. A system for pumping liquid comprising:
two liquid columns for reaching a body of liquid at their bottom, each liquid column comprising a liquid level detector and a one-way valve allowing liquid to flow upward;
an upper conduit for sealably connecting to tops of the two liquid columns and comprising a sealable gas valve for extracting gas from the upper conduit;
an actuated conduit having ends connecting to each of the two liquid columns above their one-way valve, the actuated conduit comprising, at each end, a one-way valve allowing liquid to flow inward from each of the two columns, the actuated conduit further comprising, between its two one-way valves, a switched valve allowing liquid to flow out of the system from each one-way valve at a time; and
a controller connected to the liquid level detectors for controlling the switched valve, whereby:
extraction of a gas from the upper conduit raises liquid in each of the two liquid columns to a starting level,
as the gas valve is sealed, liquid from one of the liquid columns flows out of the system through the actuated conduit and through the switched valve; and
as the liquid level in the one of the liquid columns reaches a minimum level, the switched valve switches to allow liquid to flow from another one of the liquid columns.
2. The system of claim 1, comprising an output conduit connected to the switched valve for collecting liquid flowing out of the system.
3. The system of claim 2, comprising a turbine and a generator connected to the turbine, wherein liquid flowing out of the system through the output conduit actuates the turbine for producing electricity at the generator.
4. The system of claim 2, wherein liquid output from the output conduit is for an element selected from the group consisting of domestic, industrial and agricultural use.
5. The system of claim 1, comprising a buffer reservoir connected to the switched valve for collecting liquid flowing out of the system.
6. The system of claim 5, comprising a regulating valve connected to the buffer reservoir for regulating a flow of liquid out of the system.
7. The system of claim 6, wherein the regulating valve prevents liquid from flowing out of the system while gas is extracted from the upper conduit.
8. The system of claim 6, wherein the regulating valve and the buffer reservoir smooth out the flow of liquid out of the system.
9. The system of claim 1, wherein each one-way valve comprises a rubber ring for sealably connecting to an internal perimeter of one of the conduits or of one of the columns, and a ball located on one side of the rubber ring, the ball allowing a liquid flow when separated from the rubber ring, and preventing a liquid flow when mated with the rubber ring.
10. The system of claim 9, wherein the one-way valve further comprises a spring for maintaining the ball against the rubber ring in the absence of a liquid flow.
11. A balancing liquid pump, comprising:
a sealable gas-liquid balancing conduit;
two inlet conduits for connecting to a body of liquid at their bottom in unidirectional upward direction and for connecting to the gas-liquid balancing conduit at their top;
two unidirectional inward outlet conduits, each outlet conduit for connecting at one end to one of the inlet conduits and at another end to a common switched valve, the switched valve allowing liquid to flow out of the pump from one of the two inlet conduits at a time;
a starting system for initiating a flow of liquid from the body of liquid and for raising a level of liquid in at least one of the inlet conduits;
wherein as liquid flows out of the pump from one of the inlet conduits, a level of liquid in the one of the inlet conduits goes down, and gas in the gas-liquid balancing conduit follows the level of liquid in the one of the inlet conduit;
whereby movement of the gas in the gas-liquid balancing conduit pumps liquid from the body of liquid into another one of the inlet conduits.
12. The pump of claim 11, comprising liquid level detectors in each inlet conduit, wherein detection of a low liquid level in the one of the inlet conduits controls a change of position of the switched valve for blocking a liquid flow from the one of the inlet conduits and allowing liquid to flow out from the other one of the inlet conduits.
13. The pump of claim 12, comprising a controller connected to the liquid level detectors for controlling the starting system and the switched valve.
14. The pump of claim 11, wherein a liquid flow out of the pump is prevented during a starting phase.
15. The pump of claim 14, wherein the switched valve prevents a liquid flow out of the pump during the starting phase.
16. The pump of claim 11, wherein the starting system comprises a gas valve and a gas pump for extracting gas from the gas-liquid balancing conduit during a starting phase.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A compound of formula (I):
andor its racemic mixture, enantiomers, diastereomers, tautomers, or mixtures of optional ratio, or at least one pharmaceutically acceptable salt, or solvate thereof, wherein
R1 is independently chosen from hydrogen, halo, \u2014CN, \u2014OH, optionally substituted C1-C6alkyl, optionally substituted C1-C6alkoxy, \u2014NH2, \u2014NH(C1-C4alkyl), and \u2014N(C1-C4alkyl)(C1-C4 alkyl);
R2 is aryl, or heteroaryl, each of which is optionally substituted by one or more groups selected from halo, \u2014NR5R6, \u2014OR7, \u2014S(O)nR8, \u2014C(O)R9, \u2014C(O)OR7, \u2014CN, \u2014C(O)NR5R6, \u2014NR5C(O)R9, \u2014NR5S(O)nR8, \u2014NR5S(O)nNR10R11, \u2014NR5C(O)OR7, \u2014NR5C(O)NR10R11, \u2014NO2, \u2014S(O)nNR5R6, optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted heterocycle, optionally substituted heteroaryl, optionally substituted aryl, optionally substituted alkenyl, and optionally substituted alkynyl;
L is a bond, or optionally substituted C1-C6alkylene;
W is cycloalkyl, heterocycle, aryl, or heteroaryl;
R3 is independently selected from hydrogen, -Lx-halo, -Lx-R4, -Lx-NR5R6, -Lx-OR7, -Lx-S(O)nR8, -Lx-C(O)R9, \u2014S(O)n-Lx-R8, \u2014C(O)-Lx-R9, -Lx-CN, -Lx-NR5C(O)R9, -Lx-NR5S(O)nR8, -Lx-NR5C(O)NR10R11, Lx-NR5S(O)nNR10R11, -Lx-NR5C(O)OR7, -Lx-NR5S(O)nOR7, \u2014NO2, -Lx-C(O)NR5R6, -Lx-S(O)nNR5R6, oxo(\u2550O), optionally substituted cycloalkyl, optionally substituted heterocycle, optionally substituted heteroaryl, and optionally substituted aryl,
provided when L is methylene and W is 5- or 6-membered heterocycle, R3 is independently selected from -Lx-NR5R6, -Lx-OR7, -Lx-S(O)nR8, -Lx-C(O)R9, \u2014S(O)n-Lx-R8, \u2014C(O)-Lx-R9, -Lx-CN, -Lx-NR5C(O)R9, -Lx-NR5S(O)nR8, -Lx-NR5C(O)NR10R11, -Lx-NR5S(O)nNR10R11, -Lx-NR5C(O)OR7, -Lx-NR5S(O)nOR7, \u2014NO2, -Lx-C(O)NR5R6, -Lx-S(O)nNR5R6, oxo(\u2550O), optionally substituted cycloalkyl, optionally substituted heterocycle, optionally substituted heteroaryl, and optionally substituted aryl;
R4 is C1-C6alkyl, C2-C6alkenyl, or C2-C6alkynyl, each of which is optionally substituted;
R5, R6, R7, R8, R9, R10, and R11 are independently selected from hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, and heterocycle, each of which except for hydrogen, is optionally substituted with one or more groups selected from halo, \u2014OH, \u2014O(C1-C4alkyl), \u2014CN, C1-C4alkyl, \u2014NH2, \u2014NH(C1-C4alkyl), \u2014N(C1-C4alkyl)(C1-C4alkyl), \u2014C(O)NH2, \u2014C(O)NH(C1-C4alkyl), \u2014C(O)N(C1-C4alkyl)(C1-C4alkyl), \u2014C(O)(C1-C4alkyl), \u2014NHC(O)(C1-C4alkyl), \u2014N(C1-C4alkyl)C(O)(C1-C4alkyl), \u2014S(O)nNH2, \u2014S(O)nNH(C1-C4alkyl), \u2014S(O)nN(C1-C4alkyl)(C1-C4alkyl), \u2014S(O)n(C1-C4alkyl), \u2014NHS(O)n(C1-C4alkyl), \u2014N(C1-C4alky)S(O)n(C1-C4alkyl), optionally substituted C3-C8cycloalkyl, and optionally substituted 3-8 membered heterocycle, wherein C1-C4alkyl is optionally substituted by halo, \u2014OH, \u2014OMe, \u2014CN;
or R5 and R6, R5 and R7, R5 and R8, R5 and R9, and R5 and R10 together with the atom(s) to which they are attached can form a ring, which is optionally substituted with one or more groups selected from halo, \u2014OH, \u2014O(C1-C4alkyl), \u2014CN, C1-C4alkyl, \u2014NH2, \u2014NH(C1-C4alkyl), \u2014N(C1-C4alkyl)(C1-C4alkyl), \u2014C(O)NH2, \u2014C(O)NH(C1-C4alkyl), \u2014C(O)N(C1-C4alkyl)(C1-C4alkyl), \u2014C(O)(C1-C4alkyl), \u2014NHC(O)(C1-C4alkyl), \u2014N(C1-C4alkyl)C(O)(C1-C4alkyl), \u2014S(O), NH2, \u2014S(O)nNH(C1-C4alkyl), \u2014S(O)nN(C1-C4alkyl)(C1-C4alkyl), \u2014S(O)n(C1-C4alkyl), \u2014NHS(O)n(C1-C4alkyl), \u2014N(C1-C4alky)S(O)n(C1-C4alkyl), optionally substituted C3-C8cycloalkyl, and optionally substituted 3-8 membered heterocycle, wherein C1-C4alkyl is optionally substituted by halo, \u2014OH, \u2014OMe, or CN;
Lx is a bond, or optionally substituted C1-C6alkylene;
m is 0, 1 or 2,
n is 1 or 2,
p is 1, 2 or 3.
2. (canceled)
3. The compound of claim 1, andor its racemic mixture, enantiomers, diastereomers, tautomers, or mixtures of optional ratio, or at least one pharmaceutically acceptable salt, or solvate thereof, wherein R1 is independently chosen from hydrogen, halo, \u2014CN, \u2014OH; or is chosen from methyl, ethyl, n-propyl, i-propyl, \u2014NH2, N-methylamino, N,N-dimethylamino, N-ethylamino, N-n-propylamino, N-i-propylamino, methoxy, ethoxy, propoxy, isopropoxy, each of which is optionally substituted.
4. (canceled)
5. (canceled)
6. The compound of claim 1, andor its racemic mixture, enantiomers, diastereomers, tautomers, or mixtures of optional ratio, or at least one pharmaceutically acceptable salt, or solvate thereof, wherein R2 is C5-C10aryl, or 5-10 membered heteroaryl, each of which is optionally substituted by one or more groups selected from halo, \u2014NR5R6, \u2014OR7, \u2014S(O)nR8, \u2014C(O)R9, \u2014C(O)OR7, \u2014CN, \u2014C(O)NR5R6, \u2014NR5C(O)R9, \u2014NR5S(O)nR8, \u2014NR5S(O)nNR10R11, \u2014NR5C(O)OR7, \u2014NR5C(O)NR10R11, \u2014NO2, \u2014S(O)nNR5R6, optionally substituted C1-C6 alkyl, optionally substituted C3-C8 cycloalkyl, optionally substituted 3-8 membered heterocycle, optionally substituted 5-10 membered heteroaryl, optionally substituted C5-C10 aryl, optionally substituted C2-C6 alkenyl, and optionally substituted C2-C6 alkynyl,
R5, R6, R7, R8, R9, R10, and R11 are independently selected from hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, and heterocycle, each of which except for hydrogen, is optionally substituted with one or more groups selected from halo, \u2014OH, \u2014O(C1-C4alkyl), \u2014CN, C1-C4alkyl, \u2014NH2, \u2014NH(C1-C4alkyl), \u2014N(C1-C4alkyl)(C1-C4alkyl), \u2014C(O)NH2, \u2014C(O)NH(C1-C4alkyl), \u2014C(O)N(C1-C4alkyl)(C1-C4alkyl), \u2014C(O)(C1-C4alkyl), \u2014NHC(O)(C1-C4alkyl), \u2014N(C1-C4alkyl)C(O)(C1-C4alkyl), \u2014S(O)nNH2, \u2014S(O)nNH(C1-C4alkyl), \u2014S(O)nN(C1-C4alkyl)(C1-C4alkyl), \u2014S(O)n(C1-C4alkyl), \u2014NHS(O)n(C1-C4alkyl), \u2014N(C1-C4alky)S(O)n(C1-C4alkyl), optionally substituted C3-C8cycloalkyl, and optionally substituted 3-8 membered heterocycle, wherein C1-C4alkyl is optionally substituted by halo, \u2014OH, \u2014OMe, \u2014CN;
or R5 and R6, R5 and R7, R5 and R8, R5 and R9, and R5 and R10 together with the atom(s) to which they are attached can form a ring, which is optionally substituted with one or more groups selected from halo, \u2014OH, \u2014O(C1-C4alkyl), \u2014CN, C1-C4alkyl, \u2014NH2, \u2014NH(C1-C4alkyl), \u2014N(C1-C4alkyl)(C1-C4alkyl), \u2014C(O)NH2, \u2014C(O)NH(C1-C4alkyl), \u2014C(O)N(C1-C4alkyl)(C1-C4alkyl), \u2014C(O)(C1-C4alkyl), \u2014NHC(O)(C1-C4alkyl), \u2014N(C1-C4alkyl)C(O)(C1-C4alkyl), \u2014S(O)nNH2, \u2014S(O)nNH(C1-C4alkyl), \u2014S(O)nN(C1-C4alkyl)(C1-C4alkyl), \u2014S(O)n(C1-C4alkyl), \u2014NHS(O)n(C1-C4alkyl), \u2014N(C1-C4alky)S(O)n(C1-C4alkyl), optionally substituted C3-C8cycloalkyl, and optionally substituted 3-8 membered heterocycle, wherein C1-C4alkyl is optionally substituted by halo, \u2014OH, \u2014OMe, or CN.
7. The compound of claim 6, andor its racemic mixture, enantiomers, diastereomers, tautomers, or mixtures of optional ratio, or at least one pharmaceutically acceptable salt, or solvate thereof, wherein R2 is independently chosen from phenyl, naphthyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl pyrazolyl, imidazolinyl, oxazolyl, isoxazolyl, thiazolyl, thienyl, furyl, benzofuryl, benzothienyl, benzoimidazolinyl, indolyl, indazolyl, quinolinyl, and, indanyl, indolinyl, indolin-2-one, 2,3-dihydrobenzofuryl, benzod1,3dioxolyl, and 1,2,3,4-tetrahydroquinolinyl, chroman, 2,3-dihydrobenzob1,4dioxinyl, 3,4-dihydro-2H-benzob1,4oxazinyl, isochroman, 1,3-dihydroisobenzofuryl, 1H-benzod1,3oxazin-2(4H)-onyl, each of which is optionally substituted by one or more groups selected from halo, \u2014NR5R6, \u2014OR7, \u2014S(O)nR8, \u2014C(O)R9, \u2014C(O)OR7, \u2014CN, \u2014C(O)NR5R6, \u2014NR5C(O)R9, \u2014NR5S(O)nR8, \u2014NR5S(O)nNR10R11, \u2014NR5C(O)OR7, \u2014NR5C(O)NR10R11, \u2014NO2, and \u2014S(O)nNR5R6; or selected from methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, and t-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, pyrrolidinyl, tetrahydrofuryl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, homomorpholinyl, thiomorpholinyl, diazepanyl, oxazepanyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrroly, l pyrazolyl, imidazolinyl, oxazolyl, isoxazolyl, thiazolyl, thienyl, furyl, benzofuryl, benzothienyl, benzoimidazolinyl, indolyl, indazolyl, quinolinyl, phenyl, and naphthyl, each of which is optionally substituted by one or more groups selected from halo, \u2014NR5R6, \u2014OR7, \u2014S(O)nR8, \u2014C(O)R9, \u2014C(O)OR7, \u2014CN, \u2014C(O)NR5R6, \u2014NR5C(O)R9, \u2014NR5S(O)nR8, \u2014NR5S(O)nNR10R11, \u2014NR5C(O)OR7, \u2014NR5C(O)NR10R11, \u2014NO2, \u2014S(O)nNR5R6, optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted heterocycle, optionally substituted heteroaryl, optionally substituted aryl, optionally substituted alkenyl, and optionally substituted alkynyl,
R5, R6, R7, R8, R9, R10, and R11 are independently selected from hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, and heterocycle, each of which except for hydrogen, is optionally substituted with one or more groups selected from halo, \u2014OH, \u2014O(C1-C4alkyl), \u2014CN, C1-C4alkyl, \u2014NH2, \u2014NH(C1-C4alkyl), \u2014N(C1-C4alkyl)(C1-C4alkyl), \u2014C(O)NH2, \u2014C(O)NH(C1-C4alkyl), \u2014C(O)N(C1-C4alkyl)(C1-C4alkyl), \u2014C(O)(C1-C4alkyl), \u2014NHC(O)(C1-C4alkyl), \u2014N(C1-C4alkyl)C(O)(C1-C4alkyl), \u2014S(O)nNH2, \u2014S(O)NH(C1-C4alkyl), \u2014S(O)nN(C1-C4alkyl)(C1-C4alkyl), \u2014S(O)n(C1-C4alkyl), \u2014NHS(O)n(C1-C4alkyl), \u2014N(C1-C4alky)S(O)n(C1-C4alkyl), optionally substituted C3-C8cycloalkyl, and optionally substituted 3-8 membered heterocycle, wherein C1-C4alkyl is optionally substituted by halo, \u2014OH, \u2014OMe, \u2014CN;
or R5 and R6, R5 and R7, R5 and R8, R5 and R9, and R5 and R10 together with the atom(s) to which they are attached can form a ring, which is optionally substituted with one or more groups selected from halo, \u2014OH, \u2014O(C1-C4alkyl), \u2014CN, C1-C4alkyl, \u2014NH2, \u2014NH(C1-C4alkyl), \u2014N(C1-C4alkyl)(C1-C4alkyl), \u2014C(O)NH2, \u2014C(O)NH(C1-C4alkyl), \u2014C(O)N(C1-C4alkyl)(C1-C4alkyl), \u2014C(O)(C1-C4alkyl), \u2014NHC(O)(C1-C4alkyl), \u2014N(C1-C4alkyl)C(O)(C1-C4alkyl), \u2014S(O)nNH2, S(O)nNH(C1-C4alkyl), \u2014S(O)nN(C1-C4alkyl)(C1-C4alkyl), \u2014S(O)n(C1-C4alkyl), \u2014NHS(O)n(C1-C4alkyl), \u2014N(C1-C4alky)S(O)n(C1-C4alkyl), optionally substituted C3-C8cycloalkyl, and optionally substituted 3-8 membered heterocycle, wherein C1-C4alkyl is optionally substituted by halo, \u2014OH, \u2014OMe, or CN.
8. The compound of claim 7, andor its racemic mixture, enantiomers, diastereomers, tautomers, or mixtures of optional ratio, or at least one pharmaceutically acceptable salt, or solvate thereof, wherein R2 is independently chosen from
each of which is optionally substituted by one or more groups selected from halo, \u2014NR5R6, \u2014OR7, \u2014S(O)nR8, \u2014C(O)R9, \u2014C(O)OR7, \u2014CN, \u2014C(O)NR5R6, \u2014NR5C(O)R9, \u2014NR5S(O)nR8, \u2014NR5S(O)nNR10R11, \u2014NR5C(O)OR7, \u2014NR5C(O)NR10R11, \u2014NO2, and \u2014S(O)nNR5R6; or selected from methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, and t-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, pyrrolidinyl, tetrahydrofuryl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, homomorpholinyl, thiomorpholinyl, diazepanyl, oxazepanyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrroly, l pyrazolyl, imidazolinyl, oxazolyl, isoxazolyl, thiazolyl, thienyl, furyl, benzofuryl, benzothienyl, benzoimidazolinyl, indolyl, indazolyl, quinolinyl, phenyl, and naphthyl, each of which is optionally substituted by one or more groups selected from halo, \u2014NR5R6, \u2014OR7, \u2014S(O)nR8, \u2014C(O)R9, \u2014C(O)OR7, \u2014CN, \u2014C(O)NR5R6, \u2014NR5C(O)R9, \u2014NR5S(O)nR8, \u2014NR5S(O)nNR10R11, \u2014C(O)OR7, \u2014NR5C(O)NR10R11, \u2014NO2, \u2014S(O)nNR5R6, optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted heterocycle, optionally substituted heteroaryl, optionally substituted aryl, optionally substituted alkenyl, and optionally substituted alkynyl,
R5, R6, R7, R8, R9, R10, and R11 are independently selected from hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, and heterocycle, each of which except for hydrogen, is optionally substituted with one or more groups selected from halo, \u2014OH, \u2014O(C1-C4 alkyl), \u2014CN, C1-C4 alkyl, \u2014NH2, \u2014NH(C1-C4 alkyl), \u2014N(C1-C4 alkyl)(C1-C4 alkyl), \u2014C(O)NH2, \u2014C(O)NH(C1-C4 alkyl), \u2014C(O)N(C1-C4 alkyl)(C1-C4 alkyl), \u2014C(O)(C1-C4 alkyl), \u2014NHC(O)(C1-C4 alkyl), \u2014N(C1-C4 alkyl)C(O)(C1-C4 alkyl), \u2014S(O)nNH2, \u2014S(O)nNH(C1-C4 alkyl), \u2014S(O)nN(C1-C4 alkyl)(C1-C4 alkyl), \u2014S(O)n(C1-C4 alkyl), \u2014NHS(O)n(C1-C4 alkyl), \u2014N(C1-C4 alky)S(O)n(C1-C4 alkyl), optionally substituted C3-C8 cycloalkyl, and optionally substituted 3-8 membered heterocycle, wherein C1-C4 alkyl is optionally substituted by halo, \u2014OH, \u2014OMe, or \u2014CN,
or R5 and R6, R5 and R7, R5 and R8, R5 and R9, and Wand R10 together with the atom(s) to which they are attached can form a ring, which is optionally substituted with one or more groups selected from halo, \u2014OH, \u2014O(C1-C4 alkyl), \u2014CN, C1-C4 alkyl, \u2014NH2, \u2014NH(C1-C4 alkyl), \u2014N(C1-C4 alkyl)(C1-C4 alkyl), \u2014C(O)NH2, \u2014C(O)NH(C1-C4 alkyl), \u2014C(O)N(C1-C4 alkyl)(C1-C4 alkyl), \u2014C(O)(C1-C4 alkyl), \u2014NHC(O)(C1-C4 alkyl), \u2014N(C1-C4 alkyl)C(O)(C1-C4 alkyl), \u2014S(O)nNH2, \u2014S(O)nNH(C1-C4 alkyl), \u2014S(O)N(C1-C4 alkyl)(C1-C4 alkyl), \u2014S(O)n(C1-C4 alkyl), \u2014NHS(O)n(C1-C4 alkyl), \u2014N(C1-C4 alky)S(O)n(C1-C4 alkyl), optionally substituted C3-C8 cycloalkyl, and optionally substituted 3-8 membered heterocycle, wherein C1-C4 alkyl is optionally substituted by halo, \u2014OH, \u2014OMe, or \u2014CN.
9. The compound of claim 8, andor its racemic mixture, enantiomers, diastereomers, tautomers, or mixtures of optional ratio, or at least one pharmaceutically acceptable salt, or solvate thereof, wherein R2 is independently chosen from
each of which is optionally substituted by one or more groups selected from halo, \u2014NR5R6, \u2014OR7, \u2014S(O)nR8, \u2014C(O)R9, \u2014C(O)OR7, \u2014CN, \u2014C(O)NR5R6, \u2014NR5C(O)R9, \u2014NR5S(O)nR8, \u2014NR5S(O)nNR10R11, \u2014NR5C(O)OR7, \u2014NR5C(O)NR10R11, \u2014NO2, and \u2014S(O)nNR5R6; or selected from methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, and t-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, pyrrolidinyl, tetrahydrofuryl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, homomorpholinyl, thiomorpholinyl, diazepanyl, oxazepanyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrroly, l pyrazolyl, imidazolinyl, oxazolyl, isoxazolyl, thiazolyl, thienyl, furyl, benzofuryl, benzothienyl, benzoimidazolinyl, indolyl, indazolyl, quinolinyl, phenyl, and naphthyl, each of which is optionally substituted by one or more groups selected from halo, \u2014NR5R6, \u2014OR7, \u2014S(O)nR8, \u2014C(O)R9, \u2014C(O)OR7, \u2014CN, \u2014C(O)NR5R6, \u2014NR5C(O)R9, \u2014NR5S(O)nR8, \u2014NR5S(O)nNR10R11, \u2014NR5C(O)OR7, \u2014NR5C(O)NR10R11, \u2014NO2, \u2014S(O)nNR5R6, optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted heterocycle, optionally substituted heteroaryl, optionally substituted aryl, optionally substituted alkenyl, and optionally substituted alkynyl,
R5, R6, R7, R8, R9, R10, and R11 are independently selected from hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, and heterocycle, each of which except for hydrogen, is optionally substituted with one or more groups selected from halo, \u2014OH, \u2014O(C1-C4 alkyl), \u2014CN, C1-C4 alkyl, \u2014NH2, \u2014NH(C1-C4 alkyl), \u2014N(C1-C4 alkyl)(C1-C4 alkyl), \u2014C(O)NH2, \u2014C(O)NH(C1-C4 alkyl), \u2014C(O)N(C1-C4 alkyl)(C1-C4 alkyl), \u2014C(O)(C1-C4 alkyl), \u2014NHC(O)(C1-C4 alkyl), \u2014N(C1-C4 alkyl)C(O)(C1-C4 alkyl), \u2014S(O)NH2, \u2014S(O)NH(C1-C4 alkyl), \u2014S(O)nN(C1-C4 alkyl)(C1-C4 alkyl), \u2014S(O)n(C1-C4 alkyl), \u2014NHS(O)n(C1-C4 alkyl), \u2014N(C1-C4 alky)S(O)n(C1-C4 alkyl), optionally substituted C3-C8 cycloalkyl, and optionally substituted 3-8 membered heterocycle, wherein C1-C4 alkyl is optionally substituted by halo, \u2014OH, \u2014OMe, or \u2014CN,
or R5 and R6, R5 and R7, R5 and R8, R5 and R9, and R5 and R10 together with the atom(s) to which they are attached can form a ring, which is optionally substituted with one or more groups selected from halo, \u2014OH, \u2014O(C1-C4 alkyl), \u2014CN, C1-C4 alkyl, \u2014NH2, \u2014NH(C1-C4 alkyl), \u2014N(C1-C4 alkyl)(C1-C4 alkyl), \u2014C(O)NH2, \u2014C(O)NH(C1-C4 alkyl), \u2014C(O)N(C1-C4 alkyl)(C1-C4 alkyl), \u2014C(O)(C1-C4 alkyl), \u2014NHC(O)(C1-C4 alkyl), \u2014N(C1-C4 alkyl)C(O)(C1-C4 alkyl), \u2014S(O)nNH2, \u2014S(O)nNH(C1-C4 alkyl), \u2014S(O)nN(C1-C4 alkyl)(C1-C4 alkyl), \u2014S(O)n(C1-C4 alkyl), \u2014NHS(O)n(C1-C4 alkyl), \u2014N(C1-C4 alky)S(O)n(C1-C4 alkyl), optionally substituted C3-C8 cycloalkyl, and optionally substituted 3-8 membered heterocycle, wherein C1-C4 alkyl is optionally substituted by halo, \u2014OH, \u2014OMe, or \u2014CN.
10. (canceled)
11. (canceled)
12. The compound of claim 11, andor its racemic mixture, enantiomers, diastereomers, tautomers, or mixtures of optional ratio, or at least one pharmaceutically acceptable salt, or solvate thereof, wherein L is a bond, or \u2014CH2\u2014, or \u2014CH2\u2014CH2\u2014.
13. The compound of claim 1, andor its racemic mixture, enantiomers, diastereomers, tautomers, or mixtures of optional ratio, or at least one pharmaceutically acceptable salt, or solvate thereof, wherein W is C3-C8cycloalkyl, 3-8 membered heterocycle, C5-C10aryl, or 5-10 membered heteroaryl.
14. The compound of claim 13, andor its racemic mixture, enantiomers, diastereomers, tautomers, or mixtures of optional ratio, or at least one pharmaceutically acceptable salt, or solvate thereof, wherein W is cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, pyrrolidinyl, tetrahydrofuryl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, homomorpholinyl, thiomorpholinyl, phenyl, naphthyl pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, pyrazolyl, imidazolinyl, oxazolyl, isoxazolyl, thiazolyl, thienyl, furyl, benzofuryl, benzothienyl, benzoimidazolinyl, indolyl, indazolyl, or quinolinyl.
15. (canceled)
16. The compound of claim 14, andor its racemic mixture, enantiomers, diastereomers, tautomers, or mixtures of optional ratio, or at least one pharmaceutically acceptable salt, or solvate thereof, wherein W is tetrahydrofuryl, tetrahydropyranyl, or morpholinyl.
17.-19. (canceled)
20. The compound of claim 1, andor its racemic mixture, enantiomers, diastereomers, tautomers, or mixtures of optional ratio, or at least one pharmaceutically acceptable salt, or solvate thereof, wherein R3 is independently selected from hydrogen, -Lx-halo, -Lx-R4, -Lx-NR5R6, -Lx-OR7, -Lx-S(O)nR8, -Lx-C(O)R9, \u2014S(O)n-Lx-R8, \u2014C(O)-Lx-R9, -Lx-CN, -Lx-NR5C(O)R9, -Lx-NR5S(O)nR8, -Lx-NR5C(O)NR10R11, -Lx-NR5S(O)nNR10R11, -Lx-NR5C(O)OR7, -Lx-NR5S(O)nOR7, \u2014NO2, -Lx-C(O)NR5R6, -Lx-S(O)nNR5R6, oxo(\u2550O), optionally substituted C3-C8cycloalkyl, optionally substituted 3-8 membered heterocycle, optionally substituted C5-C10aryl, and optionally substituted 5-10 membered heteroaryl, provided when L is methylene and W is 5- or 6-membered heterocycle, R3 is independently selected from -Lx-NR5R6, -Lx-OR7, -Lx-S(O)nR8, -Lx-C(O)R9, \u2014S(O)n-Lx-R8, \u2014C(O)-Lx-R9, -Lx-CN, -Lx-NR5C(O)R9, -Lx-NR5S(O)nR8, -Lx-NR5C(O)NR10R11, -Lx-NR5S(O)nNR10R11, -Lx-NR5C(O)OR7, -Lx-NR5S(O)nOR7, \u2014NO2, -Lx-C(O)NR5R6, -Lx-S(O)nNR5R6, oxo(\u2550O), optionally substituted C3-C8cycloalkyl, optionally substituted 3-8 membered heterocycle, optionally substituted C5-C10aryl, and optionally substituted 5-10 membered heteroaryl
R4 is optionally substituted C1-C4alkyl,
R5, R6, R7, R8, R9, R10, and R11 are independently selected from hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, and heterocycle, each of which except for hydrogen, is optionally substituted with one or more groups selected from halo, \u2014OH, \u2014O(C1-C4 alkyl), \u2014CN, C1-C4 alkyl, \u2014NH2, \u2014NH(C1-C4 alkyl), \u2014N(C1-C4 alkyl)(C1-C4 alkyl), \u2014C(O)NH2, \u2014C(O)NH(C1-C4 alkyl), \u2014C(O)N(C1-C4 alkyl)(C1-C4 alkyl), \u2014C(O)(C1-C4 alkyl), \u2014NHC(O)(C1-C4 alkyl), \u2014N(C1-C4 alkyl)C(O)(C1-C4 alkyl), \u2014S(O)NH2, \u2014S(O)NH(C1-C4 alkyl), \u2014S(O)N(C1-C4 alkyl)(C1-C4 alkyl), \u2014S(O)n(C1-C4 alkyl), \u2014NHS(O)n(C1-C4 alkyl), \u2014N(C1-C4 alky)S(O)n(C1-C4 alkyl), optionally substituted C3-C8 cycloalkyl, and optionally substituted 3-8 membered heterocycle, wherein C1-C4 alkyl is optionally substituted by halo, \u2014OH, \u2014OMe, or \u2014CN,
or R5 and R6, R5 and R7, R5 and R8, R5 and R9, and R5 and R10 together with the atom(s) to which they are attached can form a ring, which is optionally substituted with one or more groups selected from halo, \u2014OH, \u2014O(C1-C4 alkyl), \u2014CN, C1-C4 alkyl, \u2014NH2, \u2014NH(C1-C4 alkyl), \u2014N(C1-C4 alkyl)(C1-C4 alkyl), \u2014C(O)NH2, \u2014C(O)NH(C1-C4 alkyl), \u2014C(O)N(C1-C4 alkyl)(C1-C4 alkyl), \u2014C(O)(C1-C4 alkyl), \u2014NHC(O)(C1-C4 alkyl), \u2014N(C1-C4 alkyl)C(O)(C1-C4 alkyl), \u2014S(O)nNH2, \u2014S(O)NH(C1-C4 alkyl), \u2014S(O)N(C1-C4 alkyl)(C1-C4 alkyl), \u2014S(O)n(C1-C4 alkyl), \u2014NHS(O)n(C1-C4 alkyl), \u2014N(C1-C4 alky)S(O)n(C1-C4 alkyl), optionally substituted C3-C8 cycloalkyl, and optionally substituted 3-8 membered heterocycle, wherein C1-C4 alkyl is optionally substituted by halo, \u2014OH, \u2014OMe, or CN;
Lx is a bond, or optionally substituted C1-C6 alkylene.
21. The compound of claim 20, andor its racemic mixture, enantiomers, diastereomers, tautomers, or mixtures of optional ratio, or at least one pharmaceutically acceptable salt, or solvate thereof, wherein R3 is independently selected from hydrogen, -Lx-halo, -Lx-R4, -Lx-NR5R6, -Lx-OR7, -Lx-S(O)nR8, -Lx-C(O)R9, \u2014S(O)n-Lx-R8, \u2014C(O)-Lx-R9, -Lx-CN, -Lx-NR5C(O)R9, -Lx-NR5S(O)nR8, -Lx-NR5C(O)NR10R11, -Lx-NR5S(O)nNR10R11, -Lx-NR5C(O)OR7, -Lx-NR5S(O)nOR7, \u2014NO2, -Lx-C(O)NR5R6, -Lx-S(O)nNR5R6, oxo(\u2550O), or selected from cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, pyrrolidinyl, tetrahydrofuryl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, homomorpholinyl, thiomorpholinyl, diazepanyl, oxazepanyl, phenyl, naphthyl pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, pyrazolyl, imidazolinyl, oxazolyl, isoxazolyl, thiazolyl, thienyl, furyl, benzofuryl, benzothienyl, benzoimidazolinyl, indolyl, indazolyl, and quinolinyl, each of which is optionally substituted, provided when L is methylene and W is 5- or 6-membered heterocycle, R3 is independently selected from -Lx-NR5R6, -Lx-OR7, -Lx-S(O)nR8, -Lx-C(O)R9, \u2014S(O)n-Lx-R8, \u2014C(O)-Lx-R9, -Lx-CN, -Lx-NR5C(O)R9, -Lx-NR5S(O)nR8, -Lx-NR5C(O)NR10R11, -Lx-NR5S(O)nNR10R11, -Lx-NR5C(O)OR7, -Lx-NR5S(O)nOR7, \u2014NO2, -Lx-C(O)NR5R6, -Lx-S(O)nNR5R6, oxo(\u2550O),
R4 is methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, and t-butyl, each of which is optionally substituted
R5, R6, R7, R8, R9, R10, and R11 are independently selected from hydrogen, alkyl, cycloalkyl, aryl, heteroaryl, and heterocycle, each of which except for hydrogen, is optionally substituted with one or more groups selected from halo, \u2014OH, \u2014O(C1-C4 alkyl), \u2014CN, C1-C4 alkyl, \u2014NH2, \u2014NH(C1-C4 alkyl), \u2014N(C1-C4 alkyl)(C1-C4 alkyl), \u2014C(O)NH2, \u2014C(O)NH(C1-C4 alkyl), \u2014C(O)N(C1-C4 alkyl)(C1-C4 alkyl), \u2014C(O)(C1-C4 alkyl), \u2014NHC(O)(C1-C4 alkyl), \u2014N(C1-C4 alkyl)C(O)(C1-C4 alkyl), \u2014S(O)NH2, \u2014S(O)NH(C1-C4 alkyl), \u2014S(O)nN(C1-C4 alkyl)(C1-C4 alkyl), \u2014S(O)n(C1-C4 alkyl), \u2014NHS(O)n(C1-C4 alkyl), \u2014N(C1-C4 alky)S(O)n(C1-C4 alkyl), optionally substituted C3-C8 cycloalkyl, and optionally substituted 3-8 membered heterocycle, wherein C1-C4 alkyl is optionally substituted by halo, \u2014OH, \u2014OMe, or \u2014CN,
or R5 and R6, R5 and R7, R5 and R8, R5 and R9, and R5 and R10 together with the atom(s) to which they are attached can form a ring, which is optionally substituted with one or more groups selected from halo, \u2014OH, \u2014O(C1-C4 alkyl), \u2014CN, C1-C4 alkyl, \u2014NH2, \u2014NH(C1-C4 alkyl), \u2014N(C1-C4 alkyl)(C1-C4 alkyl), \u2014C(O)NH2, \u2014C(O)NH(C1-C4 alkyl), \u2014C(O)N(C1-C4 alkyl)(C1-C4 alkyl), \u2014C(O)(C1-C4 alkyl), \u2014NHC(O)(C1-C4 alkyl), \u2014N(C1-C4 alkyl)C(O)(C1-C4 alkyl), \u2014S(O)nNH2, \u2014S(O)1NH(C1-C4 alkyl), \u2014S(O)nN(C1-C4 alkyl)(C1-C4 alkyl), \u2014S(O)n(C1-C4 alkyl), \u2014NHS(O)n(C1-C4 alkyl), \u2014N(C1-C4 alky)S(O)n(C1-C4 alkyl), optionally substituted C3-C8 cycloalkyl, and optionally substituted 3-8 membered heterocycle, wherein C1-C4 alkyl is optionally substituted by halo, \u2014OH, \u2014OMe, or CN;
Lx is a bond, or optionally substituted C1-C4alkylene.
22. (canceled)
23. The compound of claim 1, andor its racemic mixture, enantiomers, diastereomers, tautomers, or mixtures of optional ratio, or at least one pharmaceutically acceptable salt, or solvate thereof, wherein R5, R6, R7, R8, R9, R10, and R11 are independently selected from hydrogen, C1-C4alkyl, C3-C8cycloalkyl, C5-C10aryl, 5-10 membered heteroaryl, and 3-8 membered heterocycle, each of which except for hydrogen, is optionally substituted with one or more groups selected from halo, \u2014OH, \u2014O(C1-C4 alkyl), \u2014CN, C1-C4 alkyl, \u2014NH2, \u2014NH(C1-C4 alkyl), \u2014N(C1-C4 alkyl)(C1-C1 alkyl), \u2014C(O)NH2, \u2014C(O)NH(C1-C4 alkyl), \u2014C(O)N(C1-C4 alkyl)(C1-C1 alkyl), \u2014C(O)(C1-C4 alkyl), \u2014NHC(O)(C1-C4 alkyl), \u2014N(C1-C4 alkyl)C(O)(C1-C4 alkyl), \u2014S(O)nNH2, \u2014S(O)nNH(C1-C4 alkyl), \u2014S(O)nN(C1-C4 alkyl)(C1-C4 alkyl), \u2014S(O)n(C1-C4 alkyl), \u2014NHS(O)n(C1-C4 alkyl), \u2014N(C1-C4 alky)S(O)n(C1-C4 alkyl), optionally substituted C3-C8 cycloalkyl, and optionally substituted 3-8 membered heterocycle, wherein C1-C4 alkyl is optionally substituted by halo, \u2014OH, \u2014OMe, or \u2014CN.
24. (canceled)
25. The compound of claim 1, andor its racemic mixture, enantiomers, diastereomers, tautomers, or mixtures of optional ratio, or at least one pharmaceutically acceptable salt, or solvate thereof, wherein R5 and R6, R5 and R7, R5 and R8, R5 and R9, and R5 and R10 together with the atom(s) to which they are attached can form a ring, which is optionally substituted with one or more groups selected from halo, \u2014OH, \u2014O(C1-C4 alkyl), \u2014CN, C1-C4 alkyl, \u2014NH2, \u2014NH(C1-C4 alkyl), \u2014N(C1-C4 alkyl)(C1-C1 alkyl), \u2014C(O)NH2, \u2014C(O)NH(C1-C4 alkyl), \u2014C(O)N(C1-C4 alkyl)(C1-C4 alkyl), \u2014C(O)(C1-C4 alkyl), \u2014NHC(O)(C1-C4 alkyl), \u2014N(C1-C4 alkyl)C(O)(C1-C4 alkyl), \u2014S(O)nNH2, \u2014S(O)nNH(C1-C4 alkyl), \u2014S(O)nN(C1-C4 alkyl)(C1-C4 alkyl), \u2014S(O)n(C1-C4 alkyl), \u2014NHS(O)n(C1-C4 alkyl), \u2014N(C1-C4 alky)S(O)n(C1-C4 alkyl), optionally substituted C3-C8 cycloalkyl, and optionally substituted 3-8 membered heterocycle, wherein C1-C4 alkyl is optionally substituted by halo, \u2014OH, \u2014OMe, or CN.
26. (canceled)
27. (canceled)
28. The compound of formula (I) according to claim 1, andor its racemic mixture, enantiomers, diastereomers, tautomers, or mixtures of optional ratio, or at least one pharmaceutically acceptable salt, or solvate thereof, wherein
R1 is independently chosen from hydrogen, halo, \u2014CN, \u2014OH; or is chosen from methyl, ethyl, n-propyl, i-propyl, \u2014NH2, N-methylamino, N,N-dimethylamino, N-ethylamino, N-n-propylamino, N-i-propylamino, methoxy, ethoxy, propoxy, isopropoxy, each of which is optionally substituted,
R2 is independently chosen from phenyl, naphthyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl pyrazolyl, imidazolinyl, oxazolyl, isoxazolyl, thiazolyl, thienyl, furyl, benzofuryl, benzothienyl, benzoimidazolinyl, indolyl, indazolyl, quinolinyl, and, indanyl, indolinyl, indolin-2-one, 2,3-dihydrobenzofuryl, benzod1,3dioxolyl, and 1,2,3,4-tetrahydroquinolinyl, chroman, 2,3-dihydrobenzob1,4dioxinyl, 3,4-dihydro-2H-benzob1,4oxazinyl, isochroman, 1,3-dihydroisobenzofuryl, 1H-benzod1,3oxazin-2(4H)-onyl, each of which is optionally substituted by one or more groups selected from halo, \u2014NR5R6, \u2014OR7, \u2014S(O)nR8, \u2014C(O)R9, \u2014C(O)OR7, \u2014CN, \u2014C(O)NR5R6, \u2014NR5C(O)R9, \u2014NR5S(O)nR8, \u2014NR5S(O)nNR10R11, \u2014NR5C(O)OR7, \u2014NR5C(O)NR10R11, \u2014NO2, and \u2014S(O)nNR5R6; or selected from methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, and t-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, pyrrolidinyl, tetrahydrofuryl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, homomorpholinyl, thiomorpholinyl, diazepanyl, oxazepanyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrroly, l pyrazolyl, imidazolinyl, oxazolyl, isoxazolyl, thiazolyl, thienyl, furyl, benzofuryl, benzothienyl, benzoimidazolinyl, indolyl, indazolyl, quinolinyl, phenyl, and naphthyl, each of which is optionally substituted by one or more groups selected from halo, \u2014NR5R6, \u2014OR7, \u2014S(O)nR8, \u2014C(O)R9, \u2014C(O)OR7, \u2014CN, \u2014C(O)NR5R6, \u2014NR5C(O)R9, \u2014NR5S(O)nR8, \u2014NR5S(O)nNR10R11, \u2014NR5C(O)OR7, \u2014NR5C(O)NR10R11, S(O)nNR5R6, optionally substituted lower alkyl, optionally substituted cycloalkyl, optionally substituted heterocycle, optionally substituted heteroaryl, optionally substituted aryl, optionally substituted alkenyl, and optionally substituted alkynyl,
L is a bond, or optionally substituted C1-C6 alkylene,
W is cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, pyrrolidinyl, tetrahydrofuryl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, homomorpholinyl, thiomorpholinyl, phenyl, naphthyl pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl, pyrazolyl, imidazolinyl, oxazolyl, isoxazolyl, thiazolyl, thienyl, furyl, benzofuryl, benzothienyl, benzoimidazolinyl, indolyl, indazolyl, or quinolinyl,
R3 is independently selected from hydrogen, -Lx-halo, -Lx-R4, -Lx-NR5R6, -Lx-OR7, -Lx-S(O)nR8, -Lx-C(O)R9, \u2014S(O)n-Lx-R8, \u2014C(O)-Lx-R9, -Lx-CN, -Lx-NR5C(O)R9, -Lx-NR5S(O)nR8, -Lx-NR5C(O)NR10R11, -Lx-NR5S(O)nNR10R11, -Lx-NR5C(O)OR7, -Lx-NR5S(O)nOR7, \u2014NO2, -Lx-C(O)NR5R6, -Lx-S(O)nNR5R6, and oxo(\u2550O), provided when L is methylene and W is 5- or 6-membered heterocycle, R3 is independently selected from -Lx-NR5R6, -Lx-OR7, -Lx-S(O)nR8, -Lx-C(O)R9, \u2014S(O)n-Lx-R8, \u2014C(O)-Lx-R9, -Lx-CN, -Lx-NR5C(O)R9, -Lx-NR5S(O)nR8, -Lx-NR5C(O)NR10R11, -Lx-NR5S(O)17NR10R11, -Lx-NR5C(O)OR7, -Lx-NR5S(O)nOR7, \u2014NO2, -Lx-C(O)NR5R6, -Lx-S(O)nNR5R6, oxo(\u2550O),
R4 is methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, and t-butyl, each of which is optionally substituted,
R5, R6, R7, R8, R9, R10, and R11 are independently selected from hydrogen, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, and t-butyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, phenyl, naphthyl, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, pyrrolyl pyrazolyl, imidazolinyl, oxazolyl, isoxazolyl, thiazolyl, thienyl, furyl, benzofuryl, benzothienyl, benzoimidazolinyl, indolyl, indazolyl, quinolinyl, pyrrolidinyl, tetrahydrofuryl, tetrahydropyranyl, piperidinyl, piperazinyl, morpholinyl, homomorpholinyl, thiomorpholinyl, diazepanyl, and oxazepanyl, each of which except for hydrogen, is optionally substituted with one or more groups selected from halo, \u2014OH, \u2014O(C1-C4 alkyl), \u2014CN, C1-C4 alkyl, \u2014NH2, \u2014NH(C1-C4 alkyl), \u2014N(C1-C4 alkyl)(C1-C4 alkyl), \u2014C(O)NH2, \u2014C(O)NH(C1-C4 alkyl), \u2014C(O)N(C1-C4 alkyl)(C1-C4 alkyl), \u2014C(O)(C1-C4 alkyl), \u2014NHC(O)(C1-C4 alkyl), \u2014N(C1-C4 alkyl)C(O)(C1-C4 alkyl), \u2014S(O)nNH2, \u2014S(O)NH(C1-C4 alkyl), \u2014S(O)nN(C1-C4 alkyl)(C1-C4 alkyl), \u2014S(O)n(C1-C4 alkyl), \u2014NHS(O)n(C1-C4 alkyl), \u2014N(C1-C4 alky)S(O)n(C1-C4 alkyl), optionally substituted C3-C8 cycloalkyl, and optionally substituted 3-8 membered heterocycle, wherein C1-C4 alkyl is optionally substituted by halo, \u2014OH, \u2014OMe, or CN,
or R5 and R6, R5 and R7, R5 and R8, R5 and R9, and R5 and R10 together with the atom(s) to which they are attached can form a ring, which is optionally substituted with one or more groups selected from halo, \u2014OH, \u2014O(C1-C4 alkyl), \u2014CN, C1-C4 alkyl, \u2014NH2, \u2014NH(C1-C4 alkyl), \u2014N(C1-C4 alkyl)(C1-C4 alkyl), \u2014C(O)NH2, \u2014C(O)NH(C1-C4 alkyl), \u2014C(O)N(C1-C4 alkyl)(C1-C4 alkyl), \u2014C(O)(C1-C4 alkyl), \u2014NHC(O)(C1-C4 alkyl), \u2014N(C1-C4 alkyl)C(O)(C1-C4 alkyl), \u2014S(O)nNH2, \u2014S(O)1NH(C1-C4 alkyl), \u2014S(O)nN(C1-C4 alkyl)(C1-C4 alkyl), \u2014S(O)n(C1-C4 alkyl), \u2014NHS(O)n(C1-C4 alkyl), \u2014N(C1-C4 alky)S(O)n(C1-C4 alkyl), optionally substituted C3-C8 cycloalkyl, and optionally substituted 3-8 membered heterocycle, wherein C1-C4 alkyl is optionally substituted by halo, \u2014OH, \u2014OMe, or CN,
Lx is a bond, or optionally substituted C1-C4alkylene,
m is 0, 1 or 2,
n is 1 or 2,
p is 1, 2 or 3.
29. (canceled)
30. The compound of claim 1, chosen from compounds 1 to 323 andor its racemic mixture, enantiomers, diastereomers, tautomers, or mixtures of optional ratio, or at least one pharmaceutically acceptable salt, or solvate thereof.
31. A composition comprising the compound of claim 1, andor its racemic mixture, enantiomers, diastereomers, tautomers, or mixtures of optional ratio, or at least one pharmaceutically acceptable salt, or solvate thereof and at least one pharmaceutically acceptable carrier.
32.-34. (canceled)
35. A method for inhibiting a Syk kinase, comprising administering to a system or a subject in need thereof a therapeutically effective amount of a compound of Formula (I) of claim 1.
36. A method for treating a Syk-mediated disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula (I) of claim 1.
37. (canceled)
38. The method of claim 36, wherein the disease is allergic asthma, allergic rhinitis, rheumatoid arthritis, multiple sclerosis, lupus, systemic lupus erythematosus, lymphoma, B cell lymphoma, T cell lymphoma, leukemia, myelodysplasic syndrome, anemia, leucopenia, neutropenia, thrombocytopenia, granuloctopenia, pancytoia or idiopathic thrombocytopenic purpura.
39. (canceled)